We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
06 March 2017
When and under what circumstances can a patent owner obtain an injunction against imminent infringement or, as expressed in the Patents Act, preparatory acts of infringement? This question is of particular interest for pharmaceutical patents during the regulatory process relating to authorisations of generic medicinal products.
The claimants were the holder and licensees of a supplementary protection certificate for the active substance tadalafil. The defendant had acquired a marketing authorisation for a pharmaceutical product containing tadalafil. In addition to obtaining the marketing authorisation, the claimants brought forward other circumstances to demonstrate that a preparatory patent infringement had occurred:
The Stockholm District Court (T 10911-15) began by reiterating the legislative history of the provision on preliminary injunctions and the considerations made when the EU Enforcement Directive was implemented into Swedish IP legislation (particularly Article 9.1a on interim injunctions against imminent infringement). The court noted that it was for the national courts to decide on the precise requirements for when imminent infringement is at hand. According to legislative history, the term 'preparation' in the Patents Act should have the same meaning as in the Penal Code. The court concluded that a preliminary injunction may therefore be granted against someone who, having the intention to commit or promote a patent infringement, procures, receives, keeps, conveys or engages in any other similar activity concerning something that is particularly suited to aid patent infringement.
The court went on to state that the defendant's failure to provide the claimants with requested confirmation could not be considered as falling under this wording. More is required to prove preparatory patent infringement.
The court considered the obtaining of marketing authorisation and submission of product samples to the Medical Products Agency. The court noted that these acts may fall under the wording of the requirements for preparatory infringement, but in any event such acts must have been carried out with the intent to commit or promote patent infringement. Although the defendant was somewhat compromised by its belated reply and stated only in general terms that it would respect valid patent rights, the court found that the facts before it were not sufficient to conclude that the defendant had obtained the marketing authorisation and submitted the product samples with the intent to commit and promote patent infringement. The request for a preliminary injunction was consequently denied.
The claimants appealed, but the appeal was later withdrawn.
The decision is a further piece of the puzzle in understanding preparatory patent infringement in the context of pharmaceutical patents.
In its reasoning, the court underlined the connection in legislative history to the Penal Code provisions on preparation of a crime. The reference to criminal law is difficult to understand in the context of civil patent law, as the provision in question specifically deals with the following:
"to present or receive money or anything else as pre-payment or payment for the crime or to procure, construct, give, receive, keep, convey or engage in any other similar activity with poison, explosive, weapon, picklock, falsification tool or other such means."
The court refrained from making a clear statement on whether marketing authorisations and product samples could be considered particularly suited for aiding patent infringement. As a result, the question remains unanswered.
In this context, it is worth highlighting a 2015 case that concerned parallel importation and its specific mechanism under EU law. The Stockholm District Court found that the application and granting of a parallel distribution (PD) notice (issued by the European Medicines Agency, following a notification of an intended parallel importation and submission of certain documentation) could constitute an act of preparatory infringement. In its assessment, and taking all circumstances into account, the court stressed that the application for a PD notice referred to the country to which the specific mechanism applied, as opposed to being a general notice or permission that could involve a non-infringing parallel importation. It therefore granted a preliminary injunction.
However, in the tadalafil case, the court was clear that it must be demonstrated that the preparatory acts are undertaken with the intent to commit or promote patent infringement. It may, of course, be difficult for a claimant to prove the defendant's intent.
The decision appears to indicate that stating in general terms that valid patent rights will be respected is sufficient to oppose claims of preparatory infringement. An explicit, binding undertaking not to launch would thus not be required, at least if there are no other circumstances suggesting such an intention.
Additional guidance from the newly implemented Patent and Market Appeal Court would be welcome and to the benefit of patent owners and potential defendants.
For further information on this topic please contact Jonas Westerberg or Ludvig Holm at Westerberg & Partners Advokatbyrå Ab by telephone (+46 8 5784 03 00) or email (firstname.lastname@example.org or email@example.com). The Westerberg & Partners Advokatbyrå Ab website can be accessed at www.westerberg.com.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.